We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Eden Research Plc | LSE:EDEN | London | Ordinary Share | GB0001646941 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.45 | 4.30 | 4.60 | 4.45 | 4.45 | 4.45 | 287,855 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 1.83M | -2.24M | -0.0042 | -10.60 | 23.73M |
Date | Subject | Author | Discuss |
---|---|---|---|
03/1/2024 13:19 | Eden Research plc @edenresearch We’re looking forward to a year of growth and the fruitful development of our relationship with @sumi_agro Poland! | supersonico | |
03/1/2024 10:21 | As they say Healthy two-way trade. | alchemy | |
03/1/2024 08:27 | It was Neuts. | timbo_slice | |
03/1/2024 08:19 | Bid up next please . That's a big spread. | alchemy | |
03/1/2024 08:16 | Someone's keen 100k buy at 8am | monet | |
02/1/2024 17:06 | Brucie5 "4. insecticide" You will see it soon as SS said on the recent Proactive video | investingisatrickygame | |
02/1/2024 17:00 | Chart does looked primed for take off. The share price moves very fast either way on newsflow. Obviously I/we have no idea whether the sales with amount to anything; so far in the share's history, they haven't. But I would say a number of things in favour (please correct if wrong!) 1. fully cashed up for next two years. 2. marketing/sales for their blockbuster, ecovelex, managed through Corteva, so now that it has emergency acceptance in Italy, there is little for EDEN to mess up. This for me is the short term driver to look forward to. 3. MEV/CED will continue to expand geographically, including US with potential multiplier effect of label extensions. 4. Insecticide: we'll believe it when we see it! I hold a modest position but delighted to see it's up by 50% from purchase price. High risk. | brucie5 | |
02/1/2024 16:46 | plenty of afternoon buys ? news coming ? leaky ship ? | jeanesy | |
02/1/2024 16:25 | You’re fighting against the tide. Momentum might only be small at the moment, but 2024 is going to be transformational for Eden. | kittybiscuits | |
02/1/2024 15:55 | Hahahaahaaaa!! The monkeys and twits haven't noticed the Bid-Offer spread, have they, ravenna23? Or don't they understand they can only lose money trying to trade this ordure? (chuckle, frappe) | neutralpov | |
02/1/2024 15:18 | I don't usually go for analysis based on years - New Years wear off but I like the promise of this one! | alchemy | |
02/1/2024 13:28 | Sports people and TV presenters collapsing that you never saw before 2021..and the Canary told you so..but everyone else seems to be 'baffled'. Chief Nerd @TheChiefNerd The data is available now. Excess deaths are rising. The life expectancy in the United States of America is falling and it isn’t because of COVID…Curious | supersonico | |
02/1/2024 12:51 | So good with words!Just to recall there was a single post last year from domeone who had been to the investor presentation . I forget their exact summary but they were pretty certain of success. There have been great posts from the select few i csll the informed positives. but they won't mind me saying that was the post of the year . | alchemy | |
02/1/2024 12:28 | Alchemy 2 Jan '24 - 08:04 - 16212 > Added a tidgy amount "Tidgy" is more accurate than "Tidy", given the tidgy nature of the shytestock, ROFL! ;D and cawfee | neutralpov | |
02/1/2024 10:05 | U.S. M&A Deals Under $1 Million | supersonico | |
02/1/2024 08:04 | Added a tidgy amount | alchemy | |
01/1/2024 23:51 | My last two predictions have been bang on thank you. First was that ITALTY approval would come through for Ecovelux and 2nd was that you wouldn’t pay up for the bet that you lost, just a matter of days after you made the wager. I was 100% correct on both. | kittybiscuits | |
01/1/2024 22:29 | KittyBiscuits 1 Jan '24 - 20:29 - 16209 > I predict California approval in January. ROTFL!!!! Which will work out exactly like all the other predictions you've made for, what's it, 15 years now, using any number of different IDs, in respect of wonderful prospects of all the shytestock companies which you've pushed.... ones in which only the directors and close mates prosper (no, you have no seat at the table, lol), and it all ends up in the hands of the prepackage-operators Genuine investors, nothing for you here, only tricks by paid ramping liars and moronic trapped bulls. Happy New Year. ;-) | neutralpov | |
01/1/2024 20:29 | I predict California approval in January. | kittybiscuits | |
01/1/2024 16:57 | Not that further proof was needed, but this odd acronym "AWGATWT" above can only be found twice in the whole of ADVFN, ever. Both occurrences in the EDEN ramping scamthread. supersonico 17/7/2023 17:32 and supersonico 1/1/2024 10:40 (chuckle) | neutralpov | |
01/1/2024 15:42 | I predict #3 UPL. | supersonico | |
01/1/2024 14:39 | The insecticide, according to Eden, has been trialled in 140 locations around the world. That kind of global trial and reach has never been done on an Eden product, has it? There are multiple interested and trialling parties for the insecticide. As AttyG says, if it is Syngenta, one might reasonably assume that they would have global right's. Furthermore, Eden's insecticide will deal with 4 insects in one application where I think the norm is 2. I stand to be corrected on that. So global right's on Eden's organic/green (status allocated or not) and micro-plastics free insecticide will surely be the biggest deal in the company's history. How could it not be?! Ecovelex hasn't reached that status yet as right's are only contracted to Corteva in Europe. If Ecovelex is a game-changer for Eden and Cedroz and Mevalone start delivering around the world including the US, primarily California, then as AttyG says, shareholders are going to do extremely well. I imagine when Mevalone California is confirmed and the insecticide deal is announced and assuming Eden clearly messages in layman's terms the real significance of these two announcements, that investors will come running into the stock and the share price will react accordingly, upwards. Again, as AttyG has stated from the Cenkos notes, Eden has very good product margins. Work out the potential profits, divide it by the shares in issue and apply your multiple of 20-30, 40 if your ambitious. All this with 20 staff and operational running costs of currently, sub £3 million per annum. | investingisatrickygame | |
01/1/2024 14:13 | I agree with all three predictions - though I too, am simply reading the tea leaves. All three are individual game changers. Any deal with Syngenta would deliver a minimum of £10m sales in year one. Syngenta (or any of the other parties trialling products with Eden) are not doing this for a £500k niche sales line - they will be doing it to replace a strong product, possibly making it organic but certainly making it micro plastic free. It would (all in my view) be the start of transitioning multiple products to Eden’s co encapsulation IP - the future’s bright, the future is sustaine outside. California approval - and I also expect this in the first quarter - will be a proper game changer for US sales and thus US recognition. The US market is in many aspects a bit of a holy grail - all one needs to do is read any of the longer Cenkos notes to understand the importance of a proper breakthrough in the US. French approval for ecovelex will inevitably lead to the rest of the EU approving ecovelex. Well, never mind the sunflowers or soybeans - we will all be rich with just one product for just one crop in just one economic grouping in just one of the three industries (Agriculture; Human health and Animal health) in which Eden’s IP can be utilised. | attyg | |
01/1/2024 12:42 | I predict#2 Syngenta. | supersonico |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions